Press Releases

Here is an up-to-date collection of any information given to the press. It’s a big collection, so try not to look at it all in one sitting.

Press Releases

Date Title and Summary Additional Formats
Toggle Summary ZIOPHARM Oncology Appoints David Mauney, M.D., as Executive Vice President and Chief Business Officer
BOSTON, Sept. 28, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focusing on new immunotherapies, announces the appointment of David Mauney, M.D., as Executive Vice President and Chief Business Officer, effective today.  ZIOPHARM also reports the details
View HTML
Toggle Summary ZIOPHARM Oncology Announces Updated Findings from Phase 1 Study of Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma Presented at American Academy of Neurological Surgery Annual Meeting
BOSTON, Sept. 18, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new immunotherapies, today announced that updated data from a subset of patients in its Phase 1 multicenter study of Ad-RTS-hIL-12 + veledimex in patients with recurrent or
View HTML
Toggle Summary ZIOPHARM to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
BOSTON, Sept. 05, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present at the Rodman & Renshaw 19 th Annual Global Investment Conference in New York on Tuesday, September 12, 2017 at 12:30 p.m. ET.
View HTML
Toggle Summary ZIOPHARM Oncology to Participate at Upcoming CAR-TCR Summit
Data Highlighting the Non-viral Sleeping Beauty Gene Delivery System to Be Presented during Oral Session
View HTML
Toggle Summary ZIOPHARM Oncology Reports Second Quarter 2017 Financial Results and Provides Update on Recent Activities
Company to Host Conference Call Today at 4:30 p.m. ET
View HTML
Toggle Summary ZIOPHARM Oncology to Host Second-Quarter 2017 Financial Results and Corporate Update Conference Call on July 31, 2017 at 4:30 p.m. ET
BOSTON, July 24, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new immunotherapies, today announced that it will host a conference call and webcast slide presentation on Monday, July 31, 2017 at 4:30 p.m.
View HTML
Toggle Summary ZIOPHARM Oncology Announces Initiation of Stereotactic Treatment Cohort in Phase 1 Study of Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma
Stereotactic Study Arm Serves as Runway to Clinical Studies of Controlled IL-12 Gene Therapy in Pediatric Patients and in Combination with Checkpoint Inhibitors
View HTML
Toggle Summary ZIOPHARM Oncology Announces Positive Updated Results of Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma at the 2017 ASCO Annual Meeting
Median Overall Survival in Expanded 20 mg Cohort Maintained at 12.5 Months and Continues to Compare Favorably to Historical Controls Impact of Steroids and Circulating Immune Cells Correlate with Immune Activation by IL-12 BOSTON, June 05, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc.
View HTML
Toggle Summary ZIOPHARM to Present at the Jefferies 2017 Global Healthcare Conference
BOSTON, June 02, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present at the Jefferies 2017 Global Healthcare Conference in New York on Friday, June 9, 2017 at 9:00 a.m. ET.
View HTML
Toggle Summary ZIOPHARM Oncology Announces Results of Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma to be Presented at the 2017 ASCO Annual Meeting
— Updated Survival Through Late May to be Presented on June 5, 2017 —
View HTML